Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Tempest Therapeutics, Inc. (TPST) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $36.81 per share as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $36.81.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $33.36.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $64.44.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $64.44.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $36.81 10-Q · filed 2026-08-13 |
| 2026-03-31 | $33.36 10-Q · filed 2026-05-14 |
| 2025-12-31 | $64.44 10-K · filed 2026-03-30 |
| 2025-09-30 | $64.44 10-Q · filed 2025-11-05 |
| 2025-06-30 | $64.44 10-Q · filed 2025-08-11 |
| 2025-03-31 | $64.44 10-Q · filed 2025-05-13 |
| 2024-12-31 | $6.62 10-K · filed 2025-03-27 |
| 2024-09-30 | $6.64 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.81 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.68 10-Q · filed 2024-05-09 |
| 2023-12-31 | $7.28 10-K · filed 2024-03-19 |
| 2023-09-30 | $5.04 10-Q · filed 2023-11-08 |
| 2023-06-30 | $5.04 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.13 10-Q · filed 2023-05-10 |
| 2022-12-31 | $6.66 10-K · filed 2023-03-22 |
| 2022-09-30 | $8.72 10-Q · filed 2022-11-08 |
| 2022-06-30 | $8.72 10-Q · filed 2022-08-15 |
| 2022-03-31 | $25.75 10-Q · filed 2022-05-13 |
| 2021-12-31 | $32.83 10-K · filed 2022-03-29 |
| 2021-09-30 | $37.48 10-Q · filed 2021-11-10 |
| 2021-06-30 | $47.63 10-Q · filed 2021-08-12 |
| 2021-03-31 | $15.49 10-Q · filed 2021-05-13 |
| 2020-12-31 | $16.34 10-K · filed 2021-03-29 |
| 2020-09-30 | $20.83 10-Q · filed 2020-11-09 |
| 2020-06-30 | $20.58 10-Q · filed 2020-08-10 |
| 2020-03-31 | $23.08 10-Q · filed 2020-05-08 |
| 2019-12-31 | $26.42 10-K · filed 2020-03-11 |
| 2019-09-30 | $29.61 10-Q · filed 2019-11-13 |
| 2019-06-30 | $30.71 10-Q · filed 2019-08-12 |
| 2019-03-31 | $34.63 10-Q · filed 2019-05-15 |
| 2018-12-31 | $38.50 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |